Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression

@article{Lecrubier1990EfficacyOR,
  title={Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression},
  author={Yves Lecrubier and Julien Daniel Guelfi},
  journal={Acta Psychiatrica Scandinavica},
  year={1990},
  volume={82}
}
The design and the main therapeutic results of 3 controlled double‐blind studies comparing moclobemide with tricyclics and/or placebo in depressed patients are presented. Moclobemide, a reversible inhibitor of monoamine oxidase (RIMA), preferentially inhibits MAO‐A. It showed good efficacy in major depression (DSM‐III), both endogenous and non‐endogenous. The 3 studies included a total of 763 patients. The therapeutic results are similar to those observed with tricyclics (2/3 good responders… Expand
Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression
  • E. Paykel
  • Psychology, Medicine
  • Acta psychiatrica Scandinavica. Supplementum
  • 1995
TLDR
The evidence indicates that moclobemide is effective in typical severe depression with melancholia rather than being limited to less lypical subtypes. Expand
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo
TLDR
It is concluded that moclobemide may be the second‐generation antidepressant doctors were waiting for, equally effective as the classical antidepressants but far better tolerated. Expand
Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia
  • H. Pétursson
  • Medicine
  • Acta psychiatrica Scandinavica. Supplementum
  • 1995
Dysthymia is a relatively common disorder and is frequently associated with other mental conditions such as major depression and anxiety. A number of controlled and uncontrolled studies haveExpand
Risk-Benefit Assessment of Newer Versus Older Monoamine Oxidase (MAO) Inhibitors
TLDR
Overall, RIMAs appear to represent therapeutic progress in the treatment of depression in terms of both efficacy and tolerability. Expand
Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression
TLDR
A series of meta-analyses of studies of the two most widely researched RIMAs, moclobemide (MOC; Aurorex) and brofaromine (BRO) confirm that both BRO and MOC are as effective as the tricyclic antidepressants, and they are better tolerated. Expand
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of majorExpand
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?
TLDR
This chapter takes a closer look at the arc of MAOI discovery and clinical use, and how these two classes of drugs compare to each other, and argues that TCAs, and particularly MAOIs, should continue to play an important role in the modern treatment of depression, especially in the treatment-resistant patient. Expand
Moclobemide (aurorix) in primary major depression
  • Z. Rihmer, J. Barsi, +4 authors A. Gabor
  • Medicine, Psychology
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 1994
1. Moclobemide (Aurorix) is a newly developed, effective, short-acting well tolerable and safe antidepressant which belongs to the new class of reversible monoamine-oxidase-A inhibitors. 2. AurorixExpand
Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
TLDR
With its efficacy against endogenous and nonendogenous depression, relatively rapid onset of antidepressant activity, and absence of carry-over effects on treatment withdrawal, moclobemide is likely to make an important contribution to the treatment of major depressive illness. Expand
Efficacy of moclobemide in different patient groups: a meta-analysis of studies
TLDR
Moclobemide shows the same efficacy in depression as tricyclics: its effects are similar in unipolar and bipolar affective disorders, and in patients with major depressive episode superimposed on dysthymia (double depression). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
Towards rational therapy with monoamine oxidase inhibitors.
  • P. Tyrer
  • Psychology, Medicine
  • The British journal of psychiatry : the journal of mental science
  • 1976
TLDR
A rational approach to the use of monoamine oxidase inhibitors (MAOIs) is outlined, and great variation in the interval between the first administration of these drugs and clinical response may account for the inconsistencies in published trials. Expand
Monoamine Oxidase Inhibitors in Bipolar Endogenous Depressives
TLDR
Patients in the depressive phase of bipolar illness refractory to treatment with tricyclics who have responded to MAOI are presented. Expand
Phenelzine and amitriptyline in the treatment of depression. A comparison of present and past studies.
TLDR
The results show both antidepressants to be effective, with the similarities between the two exceeding the differences, and the indications for the differential clinical use of both drugs in depressed outpatients. Expand
A multiple-dose, controlled study of phenelzine in depression-anxiety states.
TLDR
Phenelzine sulfate was significantly more effective than placebo in relieving symptoms of both depression and anxiety and drug dosage is an important variable influencing clinical outcome in this patient group. Expand
TREATMENT OF PREVIOUSLY INTRACTABLE DEPRESSIONS WITH TRANYLCYPROMINE AND LITHIUM
TLDR
Twenty-one depressed patients with so-called “bipolar characteristics” and treated with tranylcypromine and four out of 5 failures demonstrated an “irritable-paranoid” tableau and were diagnosed “schizoaffective” in the past. Expand
Response to phenelzine and amitriptyline in subtypes of outpatient depression.
TLDR
It is suggested that the two classes of antidepressant affect similar clinical subgroups within the outpatient depressive spectrum, with only relatively weak differences. Expand
A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.
TLDR
Patients suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment, and the overall assessment of tolerance clearly favoured placebo and moclOBemide over imipramsine. Expand
Ketazolam and Diazepam in Anxiety: A Controlled Study
Ketazolam (both in once-daily and three-times-daily dosing), diazepam, and placebo were compared for effectiveness in relieving anxious symptomatology in a clinical trial conducted with a total ofExpand
Monoamine Oxidase Inhibitors, Tyramine, and Cheese
TLDR
Marked potentiation of the pressor effects of tyramine hydrochloride, given orally and intravenously, was demonstrated in patients receiving a monoamine oxidase (MAO) inhibitor, and one of the hazards of treatment with MAO inhibitors is emphasized. Expand
Effects of Iproniazid in Depressive Syndromes
TLDR
In patients with lesions of the frontal lobes and in some psychotic states, the authors find a condition of postural plasticity in which an attitude imposed by passive movement is maintained indefinitely, or the patient may remain spontaneously immobilized in the same attitude for a long time. Expand
...
1
2
...